“This case thus illustrates a serious danger latent in the “comparative effectiveness research” approach taken by the Patient Protection and Affordable Care Act: mass studies of how different treatments affect large swaths of people are not likely to pick up the subtleties and nuances in treatment effectiveness that can vary from person to person based on a whole range factors that determine each individual’s unique biochemistry.”